# Prime Editing Driven Functional Genomics: Bridging Genotype to Phenotype in the Post-Genomic Era

**Authors:** Syeda N. Begum, Syed K. Hasan

PMC · DOI: 10.3390/ijms27041703 · International Journal of Molecular Sciences · 2026-02-10

## TL;DR

Prime editing is revolutionizing functional genomics by enabling precise, high-throughput analysis of genetic variants to better understand their biological and clinical significance.

## Contribution

The paper highlights how prime editing is advancing functional genomics by enabling systematic characterization of thousands of genetic variants.

## Key findings

- Prime editing allows for precise, high-throughput functional genomics without double-strand breaks or donor templates.
- Prime editing is enabling systematic characterization of genetic variants across disease-relevant genes.
- Prime editing represents a transformative platform for precision functional genomics and genetic disease treatment.

## Abstract

The post-genomic era, defined by large-scale sequencing initiatives, has generated an unprecedented catalogue of human genetic variation. Yet, the vast majority of genetic variants remain classified as variants of uncertain significance or are located within poorly characterized non-coding regions, thereby hindering the effective translation of genomic data into meaningful biological understanding and clinical application. Bridging this genotype-to-phenotype gap requires precise, high-throughput functional genomics. Early CRISPR–Cas9 knockout and CRISPR interference/activation (CRISPRi/a) screens mapped gene-level functions but could not assess single nucleotide variants (SNVs). Bridging this genotype-to-phenotype gap demands precise, high-throughput functional genomics. Multiplexed assays of variant effect (MAVEs), like saturation genome editing, systematically test all possible mutations using CRISPR–Cas9 and donor libraries. Base editors allow targeted single-base changes without double-strand breaks but are limited in scope, while prime editing can introduce any small substitution, insertion, or deletion without double-strand breaks (DSBs) or donor templates. This review traces the evolution of functional screens from gene-level knockouts to saturation genomic editing (SGE), and highlights how prime editing is driving a new paradigm for the systematic functional characterization of thousands of variants across disease-relevant genes. We also detail the architecture, mechanism, and progressive optimization of PE systems and their delivery methods. Collectively, prime editing stands as a transformative platform poised to accelerate precision functional genomics and advance the diagnosis and treatment of genetic diseases.

## Full-text entities

- **Genes:** SERPINA1 (serpin family A member 1) [NCBI Gene 5265] {aka A1A, A1AT, AAT, PI, PI1, PRO2275}, DBR1 (debranching RNA lariats 1) [NCBI Gene 51163] {aka XGIP}, VHL (von Hippel-Lindau tumor suppressor) [NCBI Gene 7428] {aka HRCA1, RCA1, VHL1, pVHL}, ERF (ETS2 repressor factor) [NCBI Gene 2077] {aka CHYTS, CRS4, PE-2, PE2}, PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738] {aka FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, FAH (fumarylacetoacetate hydrolase) [NCBI Gene 2184], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, HEXA (hexosaminidase subunit alpha) [NCBI Gene 3073] {aka TSD}, ATP1A3 (ATPase Na+/K+ transporting subunit alpha 3) [NCBI Gene 478] {aka AHC2, CAPOS, DEE99, DYT12, RDP}, COL7A1 (collagen type VII alpha 1 chain) [NCBI Gene 1294] {aka EBD1, EBDCT, EBR1, NDNC8}, SMARCB1 (SWI/SNF related BAF chromatin remodeling complex subunit B1) [NCBI Gene 6598] {aka BAF47, CSS3, INI-1, INI1, MRD15, PPP1R144}, CARD11 (caspase recruitment domain family member 11) [NCBI Gene 84433] {aka BENTA, BIMP3, CARMA1, IMD11, IMD11A, PPBL}, PRPH2 (peripherin 2) [NCBI Gene 5961] {aka AOFMD, AVMD, CACD2, DS, MDBS1, RDS}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, PDE6B (phosphodiesterase 6B) [NCBI Gene 5158] {aka CSNB3, CSNBAD2, GMP-PDEbeta, PDEB, RP40, rd1}, PAH (phenylalanine hydroxylase) [NCBI Gene 5053] {aka PH, PKU, PKU1}, EEF1A2 (eukaryotic translation elongation factor 1 alpha 2) [NCBI Gene 1917] {aka DEE33, EEF1AL, EF-1-alpha-2, EF1A, EIEE33, HS1}, RPE65 (retinoid isomerohydrolase RPE65) [NCBI Gene 6121] {aka BCO3, LCA2, RP20, mRPE65, p63, rd12}, NPC1 (NPC intracellular cholesterol transporter 1) [NCBI Gene 4864] {aka NPC, POGZ, SLC65A1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CFTR (CF transmembrane conductance regulator) [NCBI Gene 1080] {aka ABC35, ABCC7, CF, CFTR/MRP, MRP7, TNR-CFTR}, BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}
- **Diseases:** cytotoxicity (MESH:D064420), AATD (MESH:D019896), deficient (MESH:D007153), Leber congenital amaurosis (MESH:D057130), leukemia (MESH:D007938), muscle, cardiovascular, and hematological disorders (MESH:D018376), ocular disease (MESH:D005128), Tay-Sachs (MESH:D013661), photoreceptor degeneration (MESH:D009410), PKU (MESH:D010661), breast cancer (MESH:D001943), Cancer (MESH:D009369), chromosomal abnormalities (MESH:D002869), cystic fibrosis (MESH:D003550), chronic myelogenous leukemia (MESH:D015464), MMR (MESH:C536928), inflammatory (MESH:D007249), liver disease (MESH:D008107), injury to (MESH:D014947), hereditary cancers (MESH:D009386), Alternating Hemiplegia of (MESH:C536589), metabolic diseases (MESH:D008659), genetic disease (MESH:D030342), Duchenne muscular dystrophy (MESH:D020388), retinitis pigmentosa (MESH:D012174), RDEB (MESH:D016108), cardiomyopathies (MESH:D009202), HT1 (MESH:D020176)
- **Chemicals:** Lipofectamine 2000 (MESH:C086724), phenylalanine (MESH:D010649), PBS (-), GAG (MESH:D006025), PE (MESH:C053539), afatinib (MESH:D000077716), PE3 (MESH:C015467), Lipid (MESH:D008055), beta-sitosterol (MESH:C025473), osimertinib (MESH:C000596361), adenine (MESH:D000225), cholesterol (MESH:D002784), phospholipids (MESH:D010743), cytosine (MESH:D003596)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus (species) [taxon 12721], Moloney murine leukemia virus (no rank) [taxon 11801], Mus musculus (house mouse, species) [taxon 10090], SV40 [taxon 10633], Streptococcus pyogenes (species) [taxon 1314], Human immunodeficiency virus 1 (no rank) [taxon 11676]
- **Mutations:** T330P, D200N, T306K, T pairs into G, H840A, G-to-C, W313F, cytosine (C) to uracil (U), G pairs to T, D10A, L603W, A to C, F508del
- **Cell lines:** N2A — Mus musculus (Mouse), Mouse neuroblastoma, Cancer cell line (CVCL_0470), HT1 — Homo sapiens (Human), Hereditary angioedema, Transformed cell line (CVCL_WA80), KBM-7 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_A426), HEK3 — Homo sapiens (Human), Transformed cell line (CVCL_VP06), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), HAP1 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_Y019), K562 — Homo sapiens (Human), Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_0004), PE5 — Mus musculus (Mouse), Papilloma of the mouse skin, Cancer cell line (CVCL_1D86)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940846/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940846/full.md

## References

81 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940846/full.md

---
Source: https://tomesphere.com/paper/PMC12940846